증례 : Sunitinib 투여로 유발된 혈전성 혈소판 감소성 자반증 1예 = Case Reports : A Case of Sunitinib-Associated Thrombotic Thrombocytopenic Purpura

국문 초록 (Abstract)

혈전성 혈소판 감소성 자반증 및 용혈성 요독성 증후군은 다발성 장기 손상 및 미세혈관병증 용혈빈혈을 보이는 급성 질환으로 치료하지 않을 경우 환자의 생명을 위협하는 치명적인 질환이다. 최근 VEGFR-TKI가 혈전성 혈소판 감소성 자반증을 유발할 수 있다는 보고가 나오고 있어, 저자들은 전이성 콩팥세포암종 환자에서 수니티닙을 사용한 뒤, 혈전성 혈소판 감소성 자반증이 발생한 1예를 경험하였기에 이를 보고하는 바이다.

다국어 초록 (Multilingual Abstract)

Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP-HUS) is an acute condition with abnormalities of multiple organ systems. It is characterized by microangiopathic hemolytic anemia and thrombocytopenia. Several chemotherapeutic agents have been implicated in causing TTP-HUS. We report a case of TTP-HUS during treatment with sunitinib in a patient with metastatic renal cell carcinoma. A 53-year-old woman visited our hospital for fever and cough. She was diagnosed with sunitinib-induced TTP. Discontinuation of sunitinib and plasmapheresis improved her TTP. When she experienced disease progression after a prolonged period without treatment, sorafenib was tried, resulting in a partial response without recurrence of TTP-HUS. (Korean J Med 2013;84:303-307)

참고문헌 (Reference)

1 Eremina V, "VEGF inhibition and renal thrombotic microangiopathy" 358 : 1129-1136, 2008

2 Nzerue CM, "Thrombotic microangiopathies" 347 : 2171-2173, 2002

3 Terrell DR, "The incidence of thrombotic thrombocytopenic purpura-emolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-3 deficiency" 3 : 1432-1436, 2005

4 최문기, "TTP-HUS Associated with Sunitinib" 대한암학회 40 (40): 211-213, 2008

5 Talebi TN, "Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome" 19 : 143-145, 2012

6 Kapiteijn E, "Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome" 18 : 1745-1747, 2007

7 Papaetis GS, "Sunitinib : a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies" 23 : 377-389, 2009

8 Frangié C, "Renal thrombotic microangiopathy caused by anti-EGF-ntibody treatment for metastatic renal-ell carcinoma" 8 : 177-178, 2007

9 Franchini M, "Reduced von Willebrand factor-leaving protease levels in secondary thrombotic microangiopathies and other diseases" 33 : 787-797, 2007

10 Medina PJ, "Drug-ssociated thrombotic thrombocytopenic purpura-emolytic uremic syndrome" 8 : 286-293, 2001